Recombinant Human GALNS Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 8269-SU

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
8269-SU-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

Sf 21 (baculovirus)

Accession #

P34059

Conjugate

Unconjugated

Applications

Enzyme Activity

View all N-Acetylgalactosamine-6-Sulfatase/GALNS Proteins and Enzymes »

Product Specifications

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived human N-Acetylgalactosamine-6-Sulfatase/GALNS protein
Ala27-His522, with an N-terminal 6-His tag

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

His & Thr56

Predicted Molecular Mass

56 kDa

SDS-PAGE

53-59 kDa, reducing conditions

Activity

Measured by its ability to hydrolyze the substrate 4-Nitrocatechol Sulfate (PNCS).
The specific activity is >0.5 pmol/min/μg, as measured under the described conditions.

Formulation, Preparation and Storage

8269-SU
Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: N-Acetylgalactosamine-6-Sulfatase/GALNS

GALNS is a lysosomal sulfatase that hydrolyzes the 6-sulfate groups of the N-acetyl-D-galactosamine 6-sulfate units of chondroitin sulfate and of the D-galactose 6-sulfate units of keratan sulfate (1). The conversion to 3-oxoalanine (also known as C-formylglycine, FGly) of a cysteine residue is critical for catalytic activity of the enzyme (2). Deficiencies of this enzyme lead to Morquio A syndrome or mucopolysaccharidosis 4A (MPS4A), a lysosomal storage disorder characterized by intracellular accumulation of keratan sulfate and chondroitin-6-sulfate (3). Key clinical features of this disease include short stature, skeletal dysplasia, dental anomalies, and corneal clouding (4). Current therapeutic method for lysosomal storage diseases is enzyme replacement therapy (5).

References

  1. Tomatsu, S. et al. (1991) Biochem. Biophys. Res. Commun. 181:677.
  2. Dierks, T. et al. (1997) Proc. Natl. Acad. Sci. U. S. A. 94:11963.
  3. Rivera-Colon, Y. et al. (2013) J. Mol. Biol. 423:736.
  4. Fukuda, S. et al. (1992) J. Clin. Invest. 90:1049.
  5. Ohashi, T. (2012) Pediatr. Endocrinol. Rev. 10 Suppl 1:26.

Alternate Names

Chondroitinase, Chondroitinsulfatase, GA6S, Galactose-6-Sulfate Sulfatase, GalNAc6S Sulfatase, GALNS, GAS, MPS4A, NAcetylgalactosamine6Sulfatase

Entrez Gene IDs

2588 (Human); 50917 (Mouse); 292073 (Rat)

Gene Symbol

GALNS

UniProt

P34059

Additional N-Acetylgalactosamine-6-Sulfatase/GALNS Products

Product Documents for Recombinant Human GALNS Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human GALNS Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.